1360913-91-2

Upstream product

• 1360911-54-1 methyl 4-(2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-3-yl)benzoate hydrochloride 
• 1350761-21-5 2-bromo-4-methyl-5-(trifluoromethyl)benzaldehyde 
• 169206-55-7 2-oxo-1-oxa-3,8-diazaspiro<4.5>decane-8-carboxylic acid tert-butyl ester 
• 1360911-53-0 tert-butyl 3-[4-(methoxycarbonyl)phenyl]-2-oxo-1-oxa-3,8-diazaspiro[4.5]decane-8-carboxylate 
• 936092-88-5 4-bromo-2-methyl-1-(trifluoromethyl)benzene 
• 1360913-92-3 methyl 4-(8-(2-bromo-4-methyl-5-(trifluoromethyl)benzyl)-2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-3-yl)benzoate 
• 226396-32-3 (2,3,4-trifluorophenyl)boronic acid 
• 619-42-1 4-methoxycarbonylphenyl bromide 

Relevant academic research and scientific papers

Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective Antagonists

A series of structurally diverse azaspirodecanone and spirooxazolidinone analogues were designed and synthesized as potent and selective somatostatin receptor subtype 5 (SSTR5) antagonists. Four optimized compounds each representing a subseries showed imp

SPIROXAZOLIDINONE COMPOUNDS

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.